Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $175.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by Bank of America from $165.00 to $175.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other equities analysts also recently commented on ASND. Morgan Stanley upped their price objective on Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an equal weight rating in a research report on Thursday, May 16th. Cantor Fitzgerald cut their price target on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating on the stock in a report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $174.00 and gave the company an overweight rating in a report on Wednesday, August 21st. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They issued a buy rating and a $200.00 target price on the stock. Finally, The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a buy rating in a research note on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $187.08.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $119.15 on Wednesday. The firm has a market capitalization of $6.94 billion, a PE ratio of -12.40 and a beta of 0.63. The business has a 50 day simple moving average of $134.38 and a two-hundred day simple moving average of $138.07. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in the company. Quarry LP boosted its holdings in shares of Ascendis Pharma A/S by 257.1% in the 2nd quarter. Quarry LP now owns 2,500 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 1,800 shares in the last quarter. Algert Global LLC lifted its position in Ascendis Pharma A/S by 54.6% during the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 770 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in Ascendis Pharma A/S in the second quarter valued at approximately $2,762,000. Fred Alger Management LLC grew its holdings in Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock worth $41,879,000 after purchasing an additional 120,952 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new position in Ascendis Pharma A/S in the second quarter worth $4,931,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.